An engineered T-cell engager with selectivity for high mesothelin-expressing cells and activity in the presence of soluble mesothelin.
Antibody fragment
T-cell engager
T-cell stimulation
cancer immunotherapy
fusion protein
xenograft model
Journal
Oncoimmunology
ISSN: 2162-402X
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
2023
2023
Historique:
medline:
18
7
2023
pubmed:
17
7
2023
entrez:
17
7
2023
Statut:
epublish
Résumé
Mesothelin (MSLN) is an attractive immuno-oncology target, but the development of MSLN-targeting therapies has been impeded by tumor shedding of soluble MSLN (sMSLN), on-target off-tumor activity, and an immunosuppressive tumor microenvironment. We sought to engineer an antibody-based, MSLN-targeted T-cell engager (αMSLN/αCD3) with enhanced ability to discriminate high MSLN-expressing tumors from normal tissue, and activity in the presence of sMSLN. We also studied the
Identifiants
pubmed: 37456982
doi: 10.1080/2162402X.2023.2233401
pii: 2233401
pmc: PMC10339761
doi:
Substances chimiques
Mesothelin
J27WDC343N
GPI-Linked Proteins
0
Antineoplastic Agents
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
2233401Informations de copyright
© 2023 Numab Therapeutics AG. Published with license by Taylor & Francis Group, LLC.
Déclaration de conflit d'intérêts
All authors are employees of Numab Therapeutics AG. Research and manuscript preparation supported by Numab Therapeutics AG.
Références
Cancer Res. 2011 Sep 1;71(17):5915-22
pubmed: 21775520
Leukemia. 2016 Feb;30(2):484-91
pubmed: 26239198
Mol Cancer Ther. 2016 Jul;15(7):1648-55
pubmed: 27196771
Cancer Discov. 2021 Nov;11(11):2748-2763
pubmed: 34266984
Nature. 1985 Apr 18-24;314(6012):628-31
pubmed: 2859527
Oncoimmunology. 2016 Dec 23;6(2):e1273302
pubmed: 28344886
MAbs. 2017 Jan;9(1):68-84
pubmed: 27786600
Biomolecules. 2020 Jun 28;10(7):
pubmed: 32605175
Int J Cancer. 1992 Feb 1;50(3):373-81
pubmed: 1735605
Biomedicines. 2021 Apr 07;9(4):
pubmed: 33917081
J Hematol Oncol. 2015 Oct 08;8:111
pubmed: 26449653
Blood Cancer J. 2015 Aug 21;5:e340
pubmed: 26295610
Oncotarget. 2015 May 10;6(13):11694-703
pubmed: 26028668
Cancers (Basel). 2022 Mar 18;14(6):
pubmed: 35326701
J Clin Oncol. 2016 Dec;34(34):4171-4179
pubmed: 27863199
Hum Immunol. 2021 Feb;82(2):130-138
pubmed: 33341289
Cancers (Basel). 2021 Jan 14;13(2):
pubmed: 33466732
Front Oncol. 2018 Jul 25;8:285
pubmed: 30090763
Biomark Res. 2021 May 26;9(1):38
pubmed: 34039409
PLoS One. 2014 Dec 15;9(12):e114900
pubmed: 25506917
Blood. 2018 Dec 6;132(23):2484-2494
pubmed: 30275109
Br J Cancer. 2021 Mar;124(6):1037-1048
pubmed: 33469153
Blood. 2017 Feb 23;129(8):1039-1041
pubmed: 28031179
Nature. 1985 Jul 25-31;316(6026):354-6
pubmed: 3160953
Sci Transl Med. 2018 Oct 17;10(463):
pubmed: 30333240
Front Oncol. 2020 Nov 30;10:575737
pubmed: 33330050
EMBO Mol Med. 2021 Sep 7;13(9):e14291
pubmed: 34431224
Biomolecules. 2020 Mar 04;10(3):
pubmed: 32143496
J Clin Invest. 2016 Aug 1;126(8):3130-44
pubmed: 27454297
Oncoimmunology. 2021 Dec 2;10(1):2004661
pubmed: 35844969
Cancer Immunol Immunother. 2015 Jun;64(6):677-88
pubmed: 25742933
Proc Natl Acad Sci U S A. 2022 May 10;119(19):e2202439119
pubmed: 35512094
Cancer Res. 2014 Jun 1;74(11):2907-12
pubmed: 24824231
Clin Cancer Res. 2014 Feb 15;20(4):1020-8
pubmed: 24334761
J Hematol Oncol. 2021 May 3;14(1):75
pubmed: 33941237
Sci Rep. 2021 Jul 13;11(1):14397
pubmed: 34257348
Cell Mol Immunol. 2021 Sep;18(9):2188-2198
pubmed: 34381179
Sci Transl Med. 2019 Jun 19;11(497):
pubmed: 31217340
Anticancer Res. 2012 Dec;32(12):5151-8
pubmed: 23225411
Kidney Int. 1994 Oct;46(4):993-1001
pubmed: 7861725
PLoS One. 2012;7(7):e40157
pubmed: 22792233
Oncoimmunology. 2015 Jun 24;5(2):e1062969
pubmed: 27057429
Clin Cancer Res. 2021 Mar 1;27(5):1452-1462
pubmed: 33262134